139 related articles for article (PubMed ID: 38911557)
1. Vismodegib as an adjuvant treatment for periorbital basal cell carcinoma: a case report and review of literature.
Jabbehdari S; Veluvolu M; Kornhauser T; Jennings TA; Pemberton JD
Ann Transl Med; 2024 Jun; 12(3):54. PubMed ID: 38911557
[TBL] [Abstract][Full Text] [Related]
2. Periocular basal cell carcinoma - clinical perspectives.
Furdova A; Kapitanova K; Kollarova A; Sekac J
Oncol Rev; 2020 Feb; 14(1):420. PubMed ID: 32395200
[TBL] [Abstract][Full Text] [Related]
3. Ocular basal cell carcinoma: a brief literature review of clinical diagnosis and treatment.
Shi Y; Jia R; Fan X
Onco Targets Ther; 2017; 10():2483-2489. PubMed ID: 28507440
[TBL] [Abstract][Full Text] [Related]
4. Treatment of periocular basal cell carcinoma with neoadjuvant vismodegib.
Su MG; Potts LB; Tsai JH
Am J Ophthalmol Case Rep; 2020 Sep; 19():100755. PubMed ID: 32490287
[TBL] [Abstract][Full Text] [Related]
5. The Role of Surgery After Remission of Nonsystemic Extensive Periorbital Basal Cell Carcinoma Treated by Vismodegib: A Systematic Review.
Peillex D; Passemard L; Magnin B; Rouanet J; Pham Dang N
Dermatol Surg; 2022 Sep; 48(9):905-911. PubMed ID: 36054041
[TBL] [Abstract][Full Text] [Related]
6. [Vismodegib Therapy for Periocular Basal Cell Carcinoma].
Keserü M; Green S; Dulz S
Klin Monbl Augenheilkd; 2017 Jan; 234(1):64-69. PubMed ID: 28135752
[No Abstract] [Full Text] [Related]
7. Neoadjuvant Vismodegib and Mohs Micrographic Surgery for Locally Advanced Periocular Basal Cell Carcinoma.
González AR; Etchichury D; Gil ME; Del Aguila R
Ophthalmic Plast Reconstr Surg; 2019; 35(1):56-61. PubMed ID: 30444747
[TBL] [Abstract][Full Text] [Related]
8. Vismodegib for periocular and orbital basal cell carcinoma.
Gill HS; Moscato EE; Chang AL; Soon S; Silkiss RZ
JAMA Ophthalmol; 2013 Dec; 131(12):1591-4. PubMed ID: 24136169
[TBL] [Abstract][Full Text] [Related]
9. Vismodegib as a neoadjuvant treatment to Mohs surgery for aggressive basal cell carcinoma.
Alcalay J; Tauber G; Fenig E; Hodak E
J Drugs Dermatol; 2015 Mar; 14(3):219-23. PubMed ID: 25738842
[TBL] [Abstract][Full Text] [Related]
10. An investigator-initiated open-label clinical trial of vismodegib as a neoadjuvant to surgery for high-risk basal cell carcinoma.
Ally MS; Aasi S; Wysong A; Teng C; Anderson E; Bailey-Healy I; Oro A; Kim J; Chang AL; Tang JY
J Am Acad Dermatol; 2014 Nov; 71(5):904-911.e1. PubMed ID: 24929884
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant vismodegib in the management of locally advanced periocular basal cell carcinoma.
Curragh DS; Huilgol SC; Selva D
Eye (Lond); 2021 Oct; 35(10):2740-2745. PubMed ID: 33235336
[TBL] [Abstract][Full Text] [Related]
12. Interventions for basal cell carcinoma of the skin.
Thomson J; Hogan S; Leonardi-Bee J; Williams HC; Bath-Hextall FJ
Cochrane Database Syst Rev; 2020 Nov; 11(11):CD003412. PubMed ID: 33202063
[TBL] [Abstract][Full Text] [Related]
13. Ocular preservation with neoadjuvant vismodegib in patients with locally advanced periocular basal cell carcinoma.
Sagiv O; Nagarajan P; Ferrarotto R; Kandl TJ; Thakar SD; Glisson BS; Altan M; Esmaeli B
Br J Ophthalmol; 2019 Jun; 103(6):775-780. PubMed ID: 30021814
[TBL] [Abstract][Full Text] [Related]
14. A relative value unit-based cost comparison of treatment modalities for nonmelanoma skin cancer: effect of the loss of the Mohs multiple surgery reduction exemption.
Rogers HW; Coldiron BM
J Am Acad Dermatol; 2009 Jul; 61(1):96-103. PubMed ID: 19539843
[TBL] [Abstract][Full Text] [Related]
15. Role of Vismodegib in the Management of Advanced Periocular Basal Cell Carcinoma.
Cox KF; Margo CE
Cancer Control; 2016 Apr; 23(2):133-9. PubMed ID: 27218790
[TBL] [Abstract][Full Text] [Related]
16. Primary basosquamous carcinoma of the lower eyelid with ocular invasion A case report.
Papadopoulos GO; Charitonidi E; Filippou N; Fanidou D; Filippou D; Scandalakis P
Ann Ital Chir; 2018 Mar; 7():. PubMed ID: 29626183
[TBL] [Abstract][Full Text] [Related]
17. Vismodegib in neoadjuvant treatment of locally advanced basal cell carcinoma: First results of a multicenter, open-label, phase 2 trial (VISMONEO study): Neoadjuvant Vismodegib in Locally Advanced Basal Cell Carcinoma.
Bertrand N; Guerreschi P; Basset-Seguin N; Saiag P; Dupuy A; Dalac-Rat S; Dziwniel V; Depoortère C; Duhamel A; Mortier L
EClinicalMedicine; 2021 May; 35():100844. PubMed ID: 33997740
[TBL] [Abstract][Full Text] [Related]
18. Impact of Food and Drug Administration Approval of Vismodegib on Prevalence of Orbital Exenteration as a Necessary Surgical Treatment for Locally Advanced Periocular Basal Cell Carcinoma.
Sagiv O; Ding S; Ferrarotto R; Glisson B; Altan M; Johnson F; Elamin Y; Thakar SD; Nagarajan P; Esmaeli B
Ophthalmic Plast Reconstr Surg; 2019; 35(4):350-353. PubMed ID: 30365473
[TBL] [Abstract][Full Text] [Related]
19. Next-generation sequencing of the basal cell carcinoma miRNome and a description of novel microRNA candidates under neoadjuvant vismodegib therapy: an integrative molecular and surgical case study.
Sand M; Bechara FG; Gambichler T; Sand D; Friedländer MR; Bromba M; Schnabel R; Hessam S
Ann Oncol; 2016 Feb; 27(2):332-8. PubMed ID: 26578727
[TBL] [Abstract][Full Text] [Related]
20. Review of Targeted Therapy, Vismodegib, for the Treatment of Periocular Basal Cell Carcinoma.
Singalavanija T; Ceylanoglu KS; Juntipwong S; Beser BG; Elner VM; Worden FP; Demirci H
Ophthalmic Plast Reconstr Surg; 2024 Jan-Feb 01; 40(1):1-10. PubMed ID: 37552493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]